详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [a]Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, Suzhou Institute of Systems Medicine, Suzhou, Jiangsu, China [b]The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China

出处：

DOI：

ISSN：

关键词： Cancer immunotherapy Immune checkpoint blockade resistance CTLA-4 PD-1/PD-L1 Tumor microenvironment

摘要：

The ability of immune checkpoint inhibitors (ICIs) to reactivate the killing function of the immune system to tumor cells has led to long lasting immune response presenting highly promising clinical advances. Recently, immune checkpoint inhibitors related resistance due to the specialized tumor microenvironment has also drawn a widely attention. To overcome resistance to immune checkpoint blockade therapy, understanding the relationship of this type of therapy and tumor microenvironment is necessary and critical. This review will focus on how the tumor environment influences the effectiveness of the immunotherapeutic check inhibitors. Finally, we provide a briefly succinct glimpse into the most exciting pre-clinical discoveries and ongoing clinical trials to overcome the resistance of ICIs. Copyright © 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 3 区医学

小类 | 4 区免疫学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区免疫学

第一作者：

第一作者机构： [a]Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, Suzhou Institute of Systems Medicine, Suzhou, Jiangsu, China

共同第一作者：

通讯作者：

通讯机构： [a]Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, Suzhou Institute of Systems Medicine, Suzhou, Jiangsu, China [b]The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China [*1]Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005,Suzhou Institute of Systems Medicine, Suzhou, Jiangsu, China. [*2]The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A PD-1 /PD-L1 proximity assay as a theranostic marker for PD-1 blockade in patients with metastatic melanoma. [2]中国PD-1/PD-L1抑制剂治疗肺癌临床试验概况 [3]PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义 [4]PD-1/PD-L1抑制剂在妇科肿瘤的研究进展 [5]Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy [6]PD-1/PD-L1与食管鳞癌治疗和预后的相关性研究进展 [7]Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/ PD-L1 therapy [8]A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer [9]PD-1/PD-L1与食管鳞癌治疗和预后的相关性研究进展 [10]Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy